Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9053874 | 1.00 | LMNA (0.49) | LMNAMAPK1TSHRMAPTRECQL | |
| SCHEMBL29780034 | 1.00 | LMNA (0.49) | LMNAMAPK1TSHRMAPTRECQL | |
| SCHEMBL9054133 | 0.87 | LMNA (0.45) | LMNAMAPK1TSHRMAPTRECQL | |
| SCHEMBL9053850 | 0.86 | LMNA (0.48) | LMNAMAPK1TSHRMAPTRECQL | |
| SCHEMBL9053600 | 0.82 | LMNA (0.35) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL9053194 | 0.82 | EGFR (0.40) | LMNAMAPTALDH1A1POLBKMT2A | |
| SCHEMBL9054126 | 0.80 | LMNA (0.36) | LMNAMAPTALDH1A1POLBKMT2A | |
| SCHEMBL10890714 | 0.76 | ALDH1A1 (0.46) | LMNATSHRMAPTRECQLALDH1A1 | |
| SCHEMBL11819614 | 0.74 | LMNA (0.61) | LMNAMAPK1TSHRMAPTRECQL | |
| SCHEMBL11819609 | 0.74 | LMNA (0.61) | LMNAMAPK1TSHRMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025261741-A1 | SYNTHETIC LETHALITY TO TREAT AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | ALBERT-LUDWIGS-UNIVERSITAET FREIBURG KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2025-12-26 | — | — | WO | claimed |
| EP-4667628-A1 | SYNTHETIC LETHALITY TO TREAT AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | Albert-Ludwigs-Universität Freiburg Körperschaft des öffentlichen Rechts (DE) | 2025-12-24 | — | — | EP | claimed |
| WO-2025261741-A1 | SYNTHETIC LETHALITY TO TREAT AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | ALBERT-LUDWIGS-UNIVERSITAET FREIBURG KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667628-A1 | SYNTHETIC LETHALITY TO TREAT AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | Albert-Ludwigs-Universität Freiburg Körperschaft des öffentlichen Rechts (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | UNIV INDIANA RES & TECH CORP (US) | 2020-11-19 | — | — | US | disclosed |
| US-10407388-B2 | Thiourea derivatives as activators of RORα and pharmaceutical composition containing same | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2019-09-10 | — | — | US | disclosed |
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-05-16 | — | — | US | disclosed |
| WO-2017210242-A1 | INSULIN-NUCLEAR HORMONE CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017180988-A2 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-19 | — | — | WO | disclosed |
| US-9783592-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150320871-A1 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity | UNIV INDIANA RES & TECH CORP (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150320871-A1 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity | UNIV INDIANA RES & TECH CORP (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127088-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127088-B2 | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2011143209-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320871-A1 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity | GIPR, GLP1R, GCGR | LMNA 3486/4885MAPK1 3487/4885TSHR 33/4885 |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | LMNA 2064/4885MAPK1 2588/4885TSHR 159/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | LMNA 1671/4885MAPK1 3186/4885TSHR 557/4885 |
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | LMNA 2064/4885MAPK1 2588/4885TSHR 159/4885 |
| US-20130123178-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | GIPR, GLP1R, GCGR | LMNA 3486/4885MAPK1 3487/4885TSHR 33/4885 |
| US-10407388-B2 | Thiourea derivatives as activators of RORα and pharmaceutical composition containing same | RORA, RORB, ROR1 | LMNA 4808/4885MAPK1 306/4885TSHR 1037/4885 |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | LMNA 2064/4885MAPK1 2588/4885TSHR 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.